

Bo Wen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6384970/publications.pdf>

Version: 2024-02-01

37
papers

1,542
citations

394421

19
h-index

330143

37
g-index

37
all docs

37
docs citations

37
times ranked

2037
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo. <i>Cancer Cell</i> , 2015, 27, 589-602.	16.8	290
2	Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. <i>Journal of Clinical Investigation</i> , 2020, 130, 981-997.	8.2	146
3	Discovery of 4-((3R,4S,5R)-6-chloro-4-(3-chloro-2-fluorophenyl)-1-ethyl-2-oxodispiro[cyclohexane-1,2'-oxo]octane-1-carboxylic acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2819-2839.	6.4	143
4	Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	122
5	Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for <i>In Vivo</i> Dissolution and Absorption of Ionizable Drugs. <i>Molecular Pharmaceutics</i> , 2017, 14, 4281-4294.	4.6	94
6	Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degradator of Androgen Receptor for the Treatment of Advanced Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 13487-13509.	6.4	78
7	Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degradators of Androgen Receptor for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 12831-12854.	6.4	69
8	Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 892-913.	6.4	56
9	<i>In Vivo</i> Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. <i>Molecular Pharmaceutics</i> , 2017, 14, 4295-4304.	4.6	46
10	Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4832-4850.	6.4	45
11	Pharmacokinetic optimization of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1744-1749.	2.2	42
12	Measurement of <i>In Vivo</i> Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. <i>Molecular Pharmaceutics</i> , 2017, 14, 345-358.	4.6	39
13	Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. <i>Biomaterials</i> , 2021, 275, 120910.	11.4	37
14	Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3887-3901.	6.4	36
15	Simultaneous determination of four volatile compounds in rat plasma after oral administration of Shexiang Baoxin Pill (SBP) by HS-SPDE-GC-MS/MS and its application to pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 963, 47-53.	2.3	28
16	Diterpenoid lanceolatins A-G from <i>Cephalotaxus lanceolata</i> and their anti-inflammatory and anti-tumor activities. <i>RSC Advances</i> , 2015, 5, 4126-4134.	3.6	26
17	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 129, 162-174.	4.3	24
18	Mechanistic Fluid Transport Model to Estimate Gastrointestinal Fluid Volume and Its Dynamic Change Over Time. <i>AAPS Journal</i> , 2017, 19, 1682-1690.	4.4	22

#	ARTICLE	IF	CITATIONS
19	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€”Part 1: Fasted State Conditions. <i>Molecular Pharmaceutics</i> , 2018, 15, 5454-5467.	4.6	21
20	SD-91 as A Potent and Selective STAT3 Degradable Capable of Achieving Complete and Long-Lasting Tumor Regression. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 996-1004.	2.8	21
21	Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis. <i>Cell Reports</i> , 2021, 36, 109420.	6.4	18
22	Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. <i>Nature Communications</i> , 2021, 12, 2792.	12.8	17
23	Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation. <i>EBioMedicine</i> , 2021, 74, 103725.	6.1	16
24	Induction of glutathione biosynthesis by glycine-based treatment mitigates atherosclerosis. <i>Redox Biology</i> , 2022, 52, 102313.	9.0	15
25	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€”Part 2: Fed State. <i>Molecular Pharmaceutics</i> , 2018, 15, 5468-5478.	4.6	12
26	Application of an innovative high-throughput liquid chromatography-tandem mass spectrometry method for simultaneous analysis of 18 hazardous drugs to rule out accidental acute chemotherapy exposures in health care workers. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 794-802.	0.9	12
27	Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13994-14016.	6.4	11
28	Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4183-4196.	3.2	10
29	Triterpenoid saponins from the roots of <i>Psammosilene tunicoides</i> . <i>FÃ¼rterwÃ¼rter</i> , 2020, 144, 104596.	2.2	9
30	Merrilliadione â€” a Rare Isopropyl (13â€²11)â€”abeo-11â€”seco- Abietane Diterpene from <i>Illicium merrillianum</i> . <i>European Journal of Organic Chemistry</i> , 2014, 2014, 4753-4758.	2.4	8
31	Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113060.	5.5	7
32	Chemical constituents from the aerial parts of <i>Psammosilene tunicoides</i> . <i>Phytochemistry Letters</i> , 2014, 9, 59-66.	1.2	6
33	Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. <i>AAPS Journal</i> , 2020, 22, 3.	4.4	6
34	Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0079221.	3.2	5
35	Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 2061-2065.	1.0	2
36	Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 323-330.	2.6	2

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice. <i>Journal of the American Association for Laboratory Animal Science</i> , 2017, 56, 534-538.	1.2	1